XML 60 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Provision (Benefit) for Income Taxes from Continuing Operations

The Company’s provision (benefit) for income taxes from continuing operations consists of the following:

 

 

 

Year Ended December 31,

 

(In thousands)

 

2024

 

 

2023

 

 

2022 (1)

 

Current income tax provision (benefit):

 

 

 

 

 

 

 

 

 

U.S. federal

 

$

25,640

 

 

$

(981

)

 

$

11,169

 

U.S. state

 

 

4,259

 

 

 

722

 

 

 

4,401

 

Ireland

 

 

1,192

 

 

 

 

 

 

 

Deferred income tax provision (benefit):

 

 

 

 

 

 

 

 

 

U.S. federal

 

 

(19,870

)

 

 

10,192

 

 

 

(10,536

)

U.S. state

 

 

(1,392

)

 

 

(507

)

 

 

(3,010

)

Ireland

 

 

61,783

 

 

 

(107,064

)

 

 

 

Total tax provision (benefit)

 

$

71,612

 

 

$

(97,638

)

 

$

2,024

 

 

(1)
Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Schedule of Income (Loss) Before Provision (Benefit) for Income Taxes by Geographical Area

The distribution of the Company’s income (loss) before the provision (benefit) for income taxes by geographical area consists of the following:

 

 

 

Year Ended December 31,

 

(In thousands)

 

2024

 

 

2023

 

 

2022 (1)

 

Ireland

 

$

440,674

 

 

$

411,767

 

 

$

(32,198

)

U.S.

 

 

3,076

 

 

 

9,752

 

 

 

1,070

 

Income (loss) from continuing operations before provision (benefit) for income taxes

 

$

443,750

 

 

$

421,519

 

 

$

(31,128

)

 

(1)
Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Schedule of Components of Net Deferred Tax Assets

The components of the Company’s net deferred tax assets consist of the following:

 

 

 

December 31,

 

 

December 31,

 

(In thousands)

 

2024

 

 

2023

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

80,209

 

 

$

195,658

 

Research and development expenses

 

 

71,167

 

 

 

49,206

 

Accrued expenses and reserves

 

 

41,189

 

 

 

37,367

 

Operating lease liabilities

 

 

17,537

 

 

 

18,716

 

Share-based compensation

 

 

33,773

 

 

 

37,727

 

Tax credits

 

 

26,882

 

 

 

27,116

 

Other

 

 

3,695

 

 

 

5,582

 

Less: valuation allowance

 

 

(79,727

)

 

 

(129,296

)

Total deferred tax assets

 

 

194,725

 

 

 

242,076

 

Deferred tax liabilities:

 

 

 

 

 

 

Property, plant and equipment

 

 

(21,917

)

 

 

(26,271

)

Right-of-use assets

 

 

(16,337

)

 

 

(17,748

)

Other

 

 

(1,940

)

 

 

(2,716

)

Total deferred tax liabilities

 

 

(40,194

)

 

 

(46,735

)

Net deferred tax assets

 

$

154,531

 

 

$

195,341

 

Schedule of Activity in Valuation Allowance Associated with Deferred taxes

The activity in the valuation allowance associated with deferred taxes consists of the following:

 

(In thousands)

 

Balance at Beginning of Period (1)

 

 

(Additions) / Reductions (2)

 

 

Balance at End of Period (1)

 

Deferred tax asset valuation allowance for the year ended December 31, 2022

 

$

(249,112

)

 

$

(22,405

)

 

$

(271,517

)

Deferred tax asset valuation allowance for the year ended December 31, 2023

 

$

(271,517

)

 

$

142,221

 

 

$

(129,296

)

Deferred tax asset valuation allowance for the year ended December 31, 2024

 

$

(129,296

)

 

$

49,569

 

 

$

(79,727

)

 

(1)
Inclusive of continuing and discontinued operations for the periods prior to the Separation in November 2023.
(2)
(Additions) reductions represent continuing and discontinued operations for the periods prior to the Separation in November 2023. The reductions during the year ended December 31, 2024 primarily relate to the abandonment of certain Irish NOLs following the sale of the Athlone Facility to Novo. These NOLs were transferred from Elan Corporation, plc as part of the combination of the drug technology business of Elan Corporation, plc with the business of Alkermes, Inc. A number of restrictions applied to these NOLs thereby restricting the Company’s ability to utilize such NOLs. Following the sale of the Athlone Facility, the Company believes that its ability to utilize these NOLs is remote. The reduction during the year ended December 31, 2023 primarily relates to the partial release of the valuation allowance maintained by the Company against certain Irish net deferred tax assets. The additions in 2022 relate primarily to Irish NOLs.
Schedule of Reconciliation of Statutory Tax Rate to Effective Tax Rate

A reconciliation of the Company’s statutory tax rate to its effective tax rate is as follows:

 

 

 

Year Ended December 31,

 

 

(In thousands, except percentage amounts)

 

2024

 

 

 

2023

 

 

 

2022 (1)

 

 

Statutory tax rate

 

 

12.5

 

%

 

 

12.5

 

%

 

 

12.5

 

%

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations before income taxes at statutory rate

 

$

55,469

 

 

 

$

52,690

 

 

 

$

(3,891

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

 

 

5,607

 

 

 

 

4,177

 

 

 

 

4,347

 

 

Foreign rate differential(2)

 

 

4,844

 

 

 

 

4,701

 

 

 

 

521

 

 

Change in valuation allowance

 

 

(49,517

)

 

 

 

(142,424

)

 

 

 

1,102

 

 

Intercompany amounts(3)

 

 

708

 

 

 

 

(16,551

)

 

 

 

(1,694

)

 

Irish rate differential(4)

 

 

5,798

 

 

 

 

235

 

 

 

 

4,926

 

 

Uncertain tax positions

 

 

(667

)

 

 

 

(234

)

 

 

 

602

 

 

Non-deductible lobbying expenses

 

 

767

 

 

 

 

705

 

 

 

 

775

 

 

U.S. state income taxes, net of U.S. federal benefit

 

 

2,802

 

 

 

 

347

 

 

 

 

1,272

 

 

Foreign derived intangible income

 

 

(281

)

 

 

 

 

 

 

 

(4,530

)

 

R&D credit

 

 

(7,815

)

 

 

 

(2,823

)

 

 

 

(2,531

)

 

Abandonment of NOLs(5)

 

 

49,897

 

 

 

 

 

 

 

 

 

 

Other permanent items(6)

 

 

4,000

 

 

 

 

1,539

 

 

 

 

1,125

 

 

Income tax provision (benefit)

 

$

71,612

 

 

 

$

(97,638

)

 

 

$

2,024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effective tax rate

 

 

16.1

 

%

 

 

(23.2

)

%

 

 

(6.5

)

%

 

(1)
Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
(2)
Represents income or losses of U.S. subsidiaries, subject to tax at a rate other than the Irish statutory rate.
(3)
Intercompany amounts include cross-territory eliminations, the pre-tax effect of which has been eliminated in arriving at the Company's consolidated income (loss) before taxes from continuing operations. In 2023, this included a tax benefit of $15.7 million related to the intercompany transfer of inventory that was owned by the Company at December 31, 2023.
(4)
Represents income or losses of Irish companies subject to tax at a rate other than the Irish statutory rate.
(5)
Represents the tax effect of the abandonment of Irish NOLs following the sale of the Athlone Facility to Novo.
(6)
Other permanent items include, but are not limited to, non-deductible meals and entertainment expenses and non-deductible compensation of senior officers of the Company. For the year ended December 31, 2024, permanent items also included amounts relating to the sale of the Athlone Facility.
Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

 

 

 

Unrecognized

 

(In thousands)

Tax Benefits

 

Balance, December 31, 2021

 

$

8,372

 

Reductions based on the lapse of applicable statutes of limitations

 

 

(438

)

Additions based on tax positions related to prior periods

 

 

449

 

Additions based on tax positions related to the current period

 

 

590

 

Balance, December 31, 2022

 

$

8,973

 

Reductions based on the lapse of applicable statutes of limitations

 

 

(1,073

)

Additions based on tax positions related to the prior period

 

 

281

 

Additions based on tax positions related to the current period

 

 

558

 

Balance, December 31, 2023

 

$

8,739

 

Reductions based on the lapse of applicable statutes of limitations

 

 

(1,306

)

Additions based on tax positions related to the prior period

 

 

59

 

Additions based on tax positions related to the current period

 

 

581

 

Balance, December 31, 2024

 

$

8,073